Tuesday, 16 Oct 2018

You are here

Fixed and Tailored Rituximab Regimens Equal in ANCA Associated Vasculitis

The French Vasculitis Study Group has published the results of the MAINRITSAN2 trial designed to  compare individually tailored versus fixed-schedule rituximab (RTX) reinfusion for remission maintenance in patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAVs). 

Investigators enrolled 162 adult patients with either newly diagnosed or relapsing granulomatosis with polyangiitis (GPA) (72.2%) or microscopic polyangiitis (MPA) (27.8%).  Patients had previously received induction therapy with either cyclophosphamide (61.7%), rituximab (37.6%) or methotrexate (0.6%).

Tailored-RTX patients received a 500 mg rituximab infusion initially and were retreated only only when CD19+B lymphocytes or ANCA had reappeared or ANCA titre rose markedly, until month 18. Fixed dose RTX controls received a fixed 500 mg rituximab infusion on days 0 and 14 postrandomisation, then 6, 12 and 18 months after the first infusion. The primary endpoint was the number of relapses (new or reappearing symptom(s) or worsening disease with Birmingham Vasculitis Activity Score (BVAS)>0) at month 28.

At month 28, 21 patients had suffered 22 relapses:

  • Tailored patients = 17.3% relapse rate
  • Fixed patients =  9.9%  (p=0.22).

AAV relapse rates did not differ significantly between individually tailored and fixed-schedule rituximab regimens. However,  patients receiving tailored RTX had fewer rituximab infusions. 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

I dunno. Based on what you’re showing I would certainly favor fixed dosing. Almost 20% relapses vs only 10%. Looks to me like an underpowered study.
We need to stop letting the p-value be the final decider about what we think is important and what isn’t.

More Like This

Teenage Obesity Increases Lupus Risk

Analysis of the Black Women's Health Study shows that obesity as a teenager may be associated with increased risk of systemic lupus erythematous (SLE) in adulthood.

The relationship between obesity and SLE risk is unclear. Past studies have predominantly assessed white women, while black women have higher prevalence of both obesity and SLE.

SLE-Scleroderma Overlap Outcomes

Overlap of autoimmune disorders represents a significant diagnostic and management challenge to the rheumatologist. A novel cohort analysis of overlap between systemic sclerosis (SSc) and systemic lupus erythematous (SLE) suggests such patients tend to be younger, more frequently have PAH, but less cutaneous manifestations of SSc.

Excess Mortality in CTD or Systemic Vasculitis Patients

The Norwegian connective tissue disease (CTD) and systemic vasculitis (PSV) registry (NOSVAR) studied patient outcomes over a 15 year period and found overall mortality to be higher in the CTD compared to the PSV group.

Mortality Improves in Lupus ESRD

The past two decades have seen a significant decline in mortality among patients with lupus nephritis, U.S. registry data indicated.

Ustekinumab May be Effective in Lupus

Ronald F van Vollenhoven and colleagues have reported in Lancet that ustekinumab (UST), an interleukin-12 and -23 inhibitor, when added to usual therapy in systemic lupus erythematosus (SLE) patients, was shown to be superior to placebo at improving clinical efficacy and laboratory parameters after 6 months of therapy.